Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, Aurobindo Pharma has informed that the United States Food and Drug Administration (US FDA) inspected Unit-II, an API manufacturing facility of Apitoria Pharma, a wholly owned subsidiary of the Company, situated at Gaddapotharam, Industrial Development Area - Kazipally Industrial Area, Jinnaram Mandal, Sangareddy District, 502319, Telangana from September 7th to September 15th, 2026. The Unit has now received an Establishment Inspection Report (EIR) classifying the facility as ‘Voluntary Action Indicated’ (‘VAI’). FDA has concluded that this inspection is closed under 21 CFR 20.64(d)(3).
The above information is a part of company’s filings submitted to BSE.